Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

The potential risk of infections during (prolonged) rituximab therapy in rheumatoid arthritis.

Brinkman IH, van de Laar MA, Jansen TL, van Roon EN.

Expert Opin Drug Saf. 2011 Sep;10(5):715-26. doi: 10.1517/14740338.2011.562188. Epub 2011 Mar 15. Review.

PMID:
21401437
2.

B-cell therapies in established rheumatoid arthritis.

Leandro MJ, Becerra-Fernandez E.

Best Pract Res Clin Rheumatol. 2011 Aug;25(4):535-48. doi: 10.1016/j.berh.2011.10.005. Review.

PMID:
22137923
3.

[Rituximab in rheumatoid arthritis: a systematic review of efficacy and safety].

Hernández-Cruz B, García-Arias M, Ariza Ariza R, Martín Mola E.

Reumatol Clin. 2011 Sep-Oct;7(5):314-22. doi: 10.1016/j.reuma.2011.03.004. Epub 2011 Aug 2. Review. Spanish.

4.

[B cell depletion therapy using anti-CD20 antibodies in rheumatoid arthritis].

Yukawa N, Mimori T.

Clin Calcium. 2007 Apr;17(4):569-76. Review. Japanese.

PMID:
17404487
5.

Rituximab in rheumatoid arthritis and the risk of malignancies: report from a French cohort.

Slimani S, Lukas C, Combe B, Morel J.

Joint Bone Spine. 2011 Oct;78(5):484-7. doi: 10.1016/j.jbspin.2010.11.012. Epub 2010 Dec 31.

PMID:
21196130
6.

[Consensus on the Use of Rituximab in Rheumatoid Arthritis. A document with evidence-based recommendations. Grupo de Expertos en Rituximab. ].

Martín Mola E, Hernández B, García-Arias M, Alvaro-Gracia JM, Balsa A, Reino JG, Marenco de la Fuente JL, Martínez-Taboada V, Ivorra JA, Sanmartí R; el grupo de Expertos en Rituximab.

Reumatol Clin. 2011 Jan-Feb;7(1):30-44. doi: 10.1016/j.reuma.2010.11.002. Epub 2010 Dec 17. Spanish.

7.

Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients.

van Vollenhoven RF, Emery P, Bingham CO 3rd, Keystone EC, Fleischmann RM, Furst DE, Tyson N, Collinson N, Lehane PB.

Ann Rheum Dis. 2013 Sep 1;72(9):1496-502. doi: 10.1136/annrheumdis-2012-201956. Epub 2012 Nov 7.

8.

Predictive factors of response to rituximab therapy in rheumatoid arthritis: What do we know today?

Benucci M, Manfredi M, Puttini PS, Atzeni F.

Autoimmun Rev. 2010 Oct;9(12):801-3. doi: 10.1016/j.autrev.2010.07.006. Epub 2010 Jul 23. Review.

PMID:
20656069
9.

Late-onset neutropenia in patients with rheumatoid arthritis after treatment with rituximab.

Abdulkader R, Dharmapalaiah C, Rose G, Shand LM, Clunie GP, Watts RA.

J Rheumatol. 2014 May;41(5):858-61. doi: 10.3899/jrheum.130526. Epub 2014 Mar 15.

PMID:
24634201
10.

Rituximab for rheumatoid arthritis.

Palylyk-Colwell E, McGahan L.

Issues Emerg Health Technol. 2006 Sep;(89):1-4.

PMID:
17014062
11.

Safety and effectiveness of rituximab in patients with rheumatoid arthritis following an inadequate response to 1 prior tumor necrosis factor inhibitor: the RESET Trial.

Haraoui B, Bokarewa M, Kallmeyer I, Bykerk VP; RESET Investigators.

J Rheumatol. 2011 Dec;38(12):2548-56. doi: 10.3899/jrheum.110444. Epub 2011 Oct 1.

12.

B-cell therapies for rheumatoid arthritis.

Scher JU.

Bull NYU Hosp Jt Dis. 2012;70(3):200-3. Review.

13.

Low- versus high-dose rituximab for rheumatoid arthritis: a systematic review and meta-analysis.

Bredemeier M, de Oliveira FK, Rocha CM.

Arthritis Care Res (Hoboken). 2014 Feb;66(2):228-35. doi: 10.1002/acr.22116.

14.

Non-infectious pulmonary toxicity of rituximab: a systematic review.

Hadjinicolaou AV, Nisar MK, Parfrey H, Chilvers ER, Ostör AJ.

Rheumatology (Oxford). 2012 Apr;51(4):653-62. doi: 10.1093/rheumatology/ker290. Epub 2011 Dec 7. Review.

PMID:
22157468
15.

Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion.

Leandro MJ, Edwards JC, Cambridge G.

Ann Rheum Dis. 2002 Oct;61(10):883-8.

16.

Is an extra dose of rituximab an efficacious and safe alternative to improve outcomes in rheumatoid arthritis? Comment on the article by Vital et al.

Bredemeier M.

Ann Rheum Dis. 2014 Jun;73(6):e33. doi: 10.1136/annrheumdis-2014-205399. Epub 2014 Mar 4. No abstract available.

PMID:
24595549
17.

Epstein-Barr virus in bone marrow of rheumatoid arthritis patients predicts response to rituximab treatment.

Magnusson M, Brisslert M, Zendjanchi K, Lindh M, Bokarewa MI.

Rheumatology (Oxford). 2010 Oct;49(10):1911-9. doi: 10.1093/rheumatology/keq159. Epub 2010 Jun 14.

18.
19.

Comparative effectiveness of rituximab in combination with either methotrexate or leflunomide in the treatment of rheumatoid arthritis.

Narváez J, Díaz-Torné C, Ruiz JM, Hernández MV, Torrente-Segarra V, Ros S, Rodriguez de la Serna A, Díaz-López C, Sanmartí R, Nolla JM.

Semin Arthritis Rheum. 2011 Dec;41(3):401-5. doi: 10.1016/j.semarthrit.2011.06.005. Epub 2011 Aug 20.

PMID:
21862107
20.

Updates from B Cell Trials: Efficacy.

Cohen SB.

J Rheumatol Suppl. 2006 May;77:12-7. Review.

PMID:
16652440

Supplemental Content

Support Center